2024 UK Hospital Cancer Diagnostics Market: Supplier Shares by Test, Volume and Sales Segment Forecasts for Major Tumor Markers, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

This new report from  contains 527 pages and 37 tables.

The report is available by section, and can be customized to specific information needs and budget.

The report presents a comprehensive analysis of the UK hospital cancer diagnostics market, including:  

  • Major issues pertaining to the UK hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in UK hospitals. 
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of  leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers.


    I. Introduction
    II. Worldwide Market Overview
    III. Major Product Development Opportunities
    A. Reagent Kits and Test Systems/Panels
    B. Instrumentation
    C. Computers, Software and Automation
    D. Auxiliary Products
    IV. Design Criteria for Decentralized Testing Products
    V. Alternative Market Penetration Strategies
    A. Internal Development
    B. Collaborative Arrangements
    C. University Contracts
    D. Distribution Strategies
    VI. Potential Market Entry Barriers and Risks
    A. Market Maturity
    B. Cost Containment
    C. Competition
    D. Technological Edge and Limitations
    E. Patent Protection
    F. Regulatory Constraints
    G. Decentralized Testing Market Challenges
    VII. Worldwide Market and Technology Overview
    A. Cancer Statistics and Etiology
    1. Breast Cancer
    2. Lung Cancer
    3. Colon and Rectum Cancer
    4. Prostate Cancer
    5. Stomach Cancer
    6. Leukemia
    7. Lymphoma
    8. Oral Cancer
    9. Skin Cancer
    10. Uterine Cancer
    11. Ovarian Cancer
    12. Bladder Cancer
    (continued)
    B. Major Current and Emerging Cancer Diagnostic Tests
    1. Introduction
    2. Tumor Marker Classification
    3. ACTH
    4. Alpha-Fetoprotein (AFP)
    5. Beta-2 Microglobulin
    6. CA 15-3/27.29
    7. CA 19-9
    8. CA-125
    9. Calcitonin
    10. Carcinoembrionic Antigen (CEA)
    11. Estrogen and Progesterone Receptors
    12. Ferritin
    13. Gastrin
    14. Human Chorionic Gonadotropin (HCG)
    15. Insulin
    16. NSE
    17. Occult Blood
    18. PAP Smear/HPV
    19. Prostatic Acid Phosphatase (PAP)
    20. Prostate-Specific Antigen (PSA)
    21. Squamous Cell Carcinoma Antigen (SCC)
    22. T and B Lymphocytes
    23. TdT
    24. Thyroglobulin
    25. Tissue Polypeptide Antigen (TPA)
    26. Biochemical Tumor Markers
    27. Oncogenes
    - Abl/abl-bcr
    - AIB1
    - BCL-2
    - BRCA1
    - CD44
    - C-fos
    - C-myb
    - C-myc
    - CYP-17
    - Erb-B
    - HPC1
    - N-myc
    - P40
    - P51
    - P53
    - PIK3CA
    - PTI-1
    - Ras
    - Reg
    (continued)
    - Sis
    - Src and others
    28. Polypeptide Growth Factors
    - Basic Fibroblast Growth Factor
    - Beta-TGF
    - Cachectin (TNT)
    - Calmodulin
    - ECFR
    - Nerve Growth Factor (NGF)
    - Epidermal Growth Factor (EGF)
    - Ornithine Decarboxylase
    - Transferrin
    - Transforming Growth Factor-Alpha
    29. Ectopic Hormones
    30. Colony Stimulating Factors
    31. Lymphokines
    - Alpha-Interferon
    - B Cell Growth Factors
    - B Cell Growth Factor (BCGF)
    - Gamma-Interferon
    - Interleukin-1 (IL-1)
    - Macrophage Activating Factor
    32. Immunohistochemical Stains
    33. Emerging Tumor Markers
    - N-Acetylglucosamine
    - Actin
    - Alpha-Actin
    - Antineuronal Antibodies
    - 7B2
    - B72.3
    - Bax
    - BCD-F9
    - BLCA-4
    - Blood Group Antigens A,B,H
    - CA 50
    - CA 72-4/TAG-72
    - CA 195
    - CA-242
    - CA-549
    - CAM 26
    - CAR-3
    - Cathepsin-D
    - Chromogranin A and B
    - Cluster 1 Antigen
    - Cluster-5/5A Antigen
    - CTA
    - CU18
    - DR-70
    (continued)
    - DU-PAN-2
    - Endometrial Bleeding Associated Factor
    - Endostatin
    - Epithelial Membrane Antigen
    - Feulgen Hydrolysis
    - Fibronectin
    - FSH
    - (1->3)-L-fucosyltransferase
    - Gastrin-Releasing Peptide (GRP)
    - GDCFP-15
    - Glucagon
    - Glycoamines
    - H23
    - Her-2
    - Human Carcinoma Antigen
    - HPA
    - HSP27
    - Intermediate Filaments
    - Cytokeratins/CK18/Cyfra 21-1
    - Desmin
    - Gliofibrillary Acid Protein
    - Neurofilaments
    - Vimentin
    - KA 93
    - Kinases
    - KP16D3
    - LAI
    - Leukocyte Common Antigen
    - Lewis Antigens
    - Lysophosphatidic Acid (LPA)
    - Ma 695/Ma 552
    - MABDF3
    - MAG
    - ME1
    - Minactivin
    - MN/CA9
    - MSA
    - Mucin Cancer Antigen (MCA)
    - Multiple Tumor Suppressor 1
    - Myosin
    - NEA-130
    - NMP22
    - OA-519
    - Opioid Peptides
    - P-glycoprotein
    - Pancreatic Oncofetal Antigen (POA)
    - Placental Lactogen
    - PR92
    (continued)
    - Proliferative Index, Ki-67
    - Px
    - RB Inactivation/Deletion
    - Ret
    - SCCL 175
    - Selectin
    - Sialic Acid
    - Sialyl SSEA-1/SLX
    - SN10
    - Somatostatin
    - TA-90
    - TABA
    - Tachykinin
    - TAG 12
    - TPS
    - Troponin
    - Tubulin
    - VCAM
    - VEGF
    - Villen and others
    C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
    D. Current and Emerging Cancer Diagnostic Technologies
    1. Monoclonal and Polyclonal Antibodies
    2. Immunoassays
    3. Molecular Diagnostics
    4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
    5. Artificial Intelligence
    6. Flow Cytometry
    7. Two Dimensional Gel Electrophoresis (2-DGE)
    8. Biosensors
    9. Competing/Complementing Technologies
    E. Personal Testing
    (continued)
    VIII. Country Analysis
    A. Executive Summary
    B. Business Environment
    C. Market Structure
    D. Market Dynamics, Trends, Size and Growth
    - Volume Forecasts by Test and Market Segment
    - Sales Forecasts by Test and Market Segment
    - Major Supplier Sales and Market Shares
    IX. Competitive Profiles
    The report provides strategic assessments of over 30 leading cancer diagnostics market players
    and start-up companies with innovative technologies and products, including:
    - Abbott
    - Affymetrix
    - Beckman Coulter/Danaher
    - Becton Dickinson
    - bioMerieux
    - Bio-Rad
    - Cepheid
    - DiaSorin
    - Eiken Chemical
    - Elitech Group
    - Enzo Biochem
    - Fujirebio
    - Grifols
    - Hologic
    - Leica Biosystems
    - Ortho-Clinical Diagnostics
    - PerkinElmer
    - Qiagen
    - Roche
    - Siemens Healthineers
    - Takara Bio
    - Thermo Fisher
    - Wako and others.

    2024 Switzerland Nucleic Acid Testing (NAT) Market for 100 Assays: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

    This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years. The report

    USD 2850 View Report

    2024 Sweden Nucleic Acid Testing (NAT) Market for 100 Assays: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

    This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years. The report

    USD 2850 View Report

    2024 UK Drugs of Abuse Testing Market for 12 Assays: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

    This new 260-page report provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading

    USD 2450 View Report

    2024 UK Endocrine Function Testing Market for 20 Assays: Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Competitive Landscape, Innovative Technologies, Instrumentation Review, Opportunities for Suppliers

    This new 269-page report provides a comprehensive analysis in the UK endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares and strategic profiles of leading

    USD 2450 View Report

    Fill The Form For Sample Request

    Note : * Kindly provide us with your company id and get the sample reports at the earliest.

    There is no Reviews available